Stocktoria

IRONWOOD PHARMACEUTICALS INC IRWD

Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
-11.97
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials (annual, from 10-K)

FYRevenueNet incomeGross profitFree cash flowEquity
2025$296.2M$24.0M$127.0M-$261.8M
2024$351.4M$880,000$103.4M-$301.3M
2023$442.7M-$1.0B$183.2M-$346.3M
2022$410.6M$175.1M$273.6M$652.4M
2021$413.8M$528.4M$261.6M$605.9M
2020$389.5M$106.2M$167.0M$62.6M

Recent insider activity (Form 4)

InsiderRoleDateActionSharesPrice
Shepard Jaydirector2026-06-16Grant63,481
Kessler Marla Ldirector2026-06-16Grant63,481
Currie Mark Gdirector2026-06-16Grant63,481
Duane Jon Rdirector2026-06-16Grant63,481
DENNER ALEXANDER Jdirector2026-06-16Grant63,481
McHugh Juliedirector2026-06-16Grant63,481
McHugh Juliedirector2026-06-16Sell21,571$3.73
Moukheibir Catherinedirector2026-06-16Grant63,481

Why these scores methodology →

Piotroski F-score: 4/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -11.97 (distress)

  • Working capital / assets 0.081
  • Retained earnings / assets -4.217
  • EBIT / assets 0.248
  • Equity / liabilities -0.397

Source: SEC EDGAR filings · CIK 0001446847 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.